🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆
Clinical Trials in South Korea / NCT06939907
Starting soon Not applicable

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

NCT06939907 · tracked via the Priya Life Science South Korea tracker
Sponsor
Next Biomedical Co., Ltd
Phase
Not applicable
Started
2025-06
Last updated
2025-04-25

Condition(s) studied

Lower Gastrointestinal BleedingDiverticular Bleeding

Investigational drug(s) / intervention(s)

Nexpowder™

Nexpowder™: Nexpowder™ hemostatic powder

Study summary

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 19 years or older at the time of screening * Patients diagnosed with diverticular bleeding Exclusion Criteria: * Patients diagnosed with upper gastrointestinal bleeding

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Chungbuk National University Hospital Cheongju-si South Korea
Chungnam National University Hospital Daejeon South Korea
Chosun University Hospital Gwangju South Korea
Sejong Chungnam National University Hospital Sejong South Korea
Kangdong Kyunghee University Hospital Seoul South Korea
Yangsan Busan National University Hospital Yangsan South Korea

More Next Biomedical Co., Ltd. trials in South Korea

Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis Recruiting
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06939907 on ClinicalTrials.gov ↗ ← All trials in South Korea